Pharming Group Return On Equity vs. Profit Margin
| PHAR Stock | USD 7.74 0.27 3.61% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (0.05) | Current Value (0.05) | Quarterly Volatility 4.13820671 |
For Pharming Group profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pharming Group to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pharming Group NV utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pharming Group's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pharming Group NV over time as well as its relative position and ranking within its peers.
Pharming |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharming Group. If investors know Pharming will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharming Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share (0.27) | Revenue Per Share 4.38 | Quarterly Revenue Growth 0.122 | Return On Assets (0.01) |
The market value of Pharming Group NV is measured differently than its book value, which is the value of Pharming that is recorded on the company's balance sheet. Investors also form their own opinion of Pharming Group's value that differs from its market value or its book value, called intrinsic value, which is Pharming Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharming Group's market value can be influenced by many factors that don't directly affect Pharming Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharming Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharming Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharming Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Pharming Group NV Profit Margin vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Pharming Group's current stock value. Our valuation model uses many indicators to compare Pharming Group value to that of its competitors to determine the firm's financial worth. Pharming Group NV is considered to be number one stock in return on equity category among its peers. It is regarded second in profit margin category among its peers . At this time, Pharming Group's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pharming Group by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Pharming Profit Margin vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Pharming Group |
| = | -0.0818 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Pharming Group |
| = | (0.06) % |
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Pharming Group Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pharming Group, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pharming Group will eventually generate negative long term returns. The profitability progress is the general direction of Pharming Group's change in net profit over the period of time. It can combine multiple indicators of Pharming Group, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2.1 M | -2 M | |
| Operating Income | -4.9 M | -4.6 M | |
| Income Before Tax | -12 M | -12.6 M | |
| Total Other Income Expense Net | -7.1 M | -7.5 M | |
| Net Loss | -9.6 M | -9.1 M | |
| Income Tax Expense | -1.5 M | -1.4 M | |
| Net Interest Income | -2.4 M | -2.6 M | |
| Interest Income | 3.7 M | 2.8 M | |
| Net Loss | -10.5 M | -10 M | |
| Net Income Applicable To Common Shares | 15.7 M | 8.3 M | |
| Change To Netincome | -3.2 M | -3.1 M | |
| Net Loss | (0.01) | (0.02) | |
| Income Quality | 1.81 | 0.91 | |
| Net Income Per E B T | 0.90 | 0.85 |
Pharming Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Pharming Group. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pharming Group position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pharming Group's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Pharming Group without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Use Investing Themes to Complement your Pharming Group position
In addition to having Pharming Group in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Penny Thematic Idea Now
Penny
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.